Palestine, State of

Reimbursed Care Access

The State of Palestine is a party to the UN drug control conventions, and most classical psychedelics (psilocybin, MDMA, DMT, mescaline, 2C‑x, ibogaine, 5‑MeO‑DMT, ayahuasca) are treated under strict national controls with no authorized medical use outside approved research. Ketamine is recognized and used within health systems as an essential anesthetic and is deployed clinically (including emergency/trauma care), but licensed psychedelic psychiatric products such as esketamine (Spravato) are not established in Palestinian regulatory practice and there is no evidence of routine reimbursed psychiatric use of ketamine or esketamine. Overall access is limited to standard medical/anaesthetic settings for ketamine and otherwise to criminalized status or clinical trials for most psychedelics.